Drugs / AIR001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07431112 | Mar 2026 → Nov 2028 expected | alpha 1-antitrypsin deficiency | AIRNA Corporation | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01725269 | Mar 2013 → Apr 2014 | pulmonary arterial hypertension | Aires Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01725256 | Nov 2012 → Feb 2014 | pulmonary arterial hypertension | Aires Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01725256 ↗ |
| Modality | Oligonucleotide (other) | “AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as a single dose.” NCT07431112 ↗ |
| Route | Other | “inhaled nebulized AIR001 administered” NCT01725256 ↗ |